Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty

NCT ID: NCT02650141

Last Updated: 2019-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

143 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to various complex factors, the incidence of precocious puberty is increasing rapidly. It severely threatens physical and mental health of children. It's urgent to explore effective ways to control the disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the research, 138 precocious puberty children are randomly divided into the Ziyinxiehuo granules group (69 cases) and Zishenqinggan granules group(69 cases). Patients in Ziyinxiehuo granules group are treated with a series of experienced chinese herbal formulas, whereas the Zishenqinggan granules group received with different series of experienced chinese herbal formulas.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Precocious Puberty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ziyinxiehuo Granules

Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.

Group Type EXPERIMENTAL

ziyinxiehuo Granules

Intervention Type DRUG

Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing "Yin", removing "Fire" Usage: administered after dissolved, 3 times per day after breakfast and supper

zishenqinggan Granules

Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.

Group Type ACTIVE_COMPARATOR

zishenqinggan Granules

Intervention Type DRUG

Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing "Kidney", Clearing "Liver" Usage: administered after dissolved, 3 times per day after breakfast and supper

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ziyinxiehuo Granules

Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing "Yin", removing "Fire" Usage: administered after dissolved, 3 times per day after breakfast and supper

Intervention Type DRUG

zishenqinggan Granules

Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing "Kidney", Clearing "Liver" Usage: administered after dissolved, 3 times per day after breakfast and supper

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

nourishing"Yin"-removing"Fire" Granules replenishing "Kidney"-Clearing "Liver" Granules

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Girls are diagnosed as simple early breast development, and their age of onset is less than 8 years
* Tanner stages of breast in female patients are Tanner II and Tanner III, Diameter of mammary nucleus is less than 3cm;
* B-type ultrasonography: the size and volume of uterus and follicle is in the normal range at the same age;
* bone age: the bone age in the patients are the same with their actual age.


* Girls are diagnosed as Idiopathic central precocious puberty,and their age of onset ≤8 years
* Tanner stages of brest in female patients ≤ Tanner III stage,diameter of mammillary nucleus \< 3cm
* B-type ultrasonography: the volume of uterus≥1\~3ml,the diameter of follicle≥4mm;or the length of uterus ≥3.4-4cm
* bone age: compared the actual age ,the bone age is no more than 1 year and the bone age \<10 years old;
* in master single test: LH \>3 IU/L
* GnRH stimulation test: LH/FSH\>0.6, the Peak LH 3.5\~5.0 IU/L, the Peak LH 3.5\~5.0 IU/L.

Exclusion Criteria

* the bone age is advanced by more than 1 standard deviations for chronological age
* pseudo sexual precocity, including gonadal tumor,adrenal disease,exogenous intake induced with hormone drugs or food and multiple bone fiber structure dysplasia of precocious puberty (McCune Albright syndrome)
* heterosexual precocious puberty
2. In the mild true precocious puberty children:


* The central nervous system organic diseases caused sexual precocity
* congenital thyroid function reduce disease with precocious puberty, congenital adrenal hyperplasia, adrenal tumor
* ovarian or testicular neoplasms,
* McCune Albright syndrome (precocious puberty with polyostotic fibrous dysplasia and skin pigment abnormalities, pigmentation)
* there is a family history of diseases such as tumor, leukemia, diabetes, systemic lupus erythematosus, etc
* precocious puberty and partial precocious puberty
Maximum Eligible Age

8 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital of Fudan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jian Yu

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jian Y Jian, professor

Role: STUDY_CHAIR

Children Hospital of Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Chinses Traditional Medcine; Children Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Sun W, Han X, Wang Y, Yu J, Yan W, Zhao J, Chen W, Xue Z. Effectiveness of ZiYin Xiehuo granules and Zishen Qinggan granules on partial precocious puberty in girls: a multicenter, randomized, single-blind, controlled trial. J Tradit Chin Med. 2018 Oct;38(5):740-745.

Reference Type RESULT
PMID: 32185991 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NO.12401905505

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of Chinese Herbal Therapy for Asthma
NCT00712296 TERMINATED PHASE1/PHASE2